Targeting DXP synthase in bacterial metabolism
- Institution
- Johns Hopkins University, MD
- Principal investigator
- Caren L. Freel Meyers
- Funding
- $454K
- Duration
- 2021–2027
Moonbase score
Still being scored
Abstract
There is an urgent need to develop new antimicrobial strategies to combat the increasing occurrence of drug resistance in clinical pathogens. Current antibiotics act on a limited set of cellular processes, and the rate of new inhibitor discovery is rapidly declining. With the diminishing arsenal of useful antibiotics, other essential cellular processes must be explored as antibacterial targets. During infection, bacterial pathogens rapidly respond to changes in the host microenvironment by remodeling metabolism to promote growth. These “metabolic adaptations” are crucial for pathogen survival and pathogenicity in vivo and are thus a promising target space for antibiotic development. Positioned at a metabolic branch point to supply essential vitamins and isoprenoids, 1-deoxy-D-xylulose 5-phosphate synthase (DXPS) is poised to be a key player in bacterial metabolic adaptation during infection, thus it is a potential target. We have uncovered several unique features of DXPS structure and mechanism that have guided the development of selective inhibitors that exert antibacterial activity by a mechanism involving DXPS inhibition. Our research will test the hypothesis that inhibition of DXPS will severely hinder pathogen metabolic adaptation in the host and take the next steps to develop antibacterial strategies targeting DXPS in clinical pathogens.
LOADING MOONBASE SCORE
Questions for Johns Hopkins University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Johns Hopkins UniversityNot yet scored
Pharmacology and Molecular Sciences Training Program
Caren L. Freel Meyers · $479K · 2020–2030
- NIH · Johns Hopkins University72
Development, Piloting and Dissemination of an Integrated Clinical and Social Multi-level Decision Support Platform to Address Social Determinants of Health Among Minority Populations in Baltimore City
Elham Hatef-Naimi · $611K · 2021–2025
- NIH · Johns Hopkins University66
Glucose instability and neurocognitive outcomes in older adults
Elizabeth Selvin · $697K · 2021–2027